These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26088547)

  • 1. Polymyxin B Induced Generalized Hyperpigmentation in Neonates.
    Gothwal S; Meena K; Sharma SD
    Indian J Pediatr; 2016 Feb; 83(2):179-80. PubMed ID: 26088547
    [No Abstract]   [Full Text] [Related]  

  • 2. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.
    Mattos KPH; Cintra ML; Gouvêa IR; Ferreira LÁ; Velho PENF; Moriel P
    J Clin Pharm Ther; 2017 Oct; 42(5):573-578. PubMed ID: 28497462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.
    Zavascki AP; Schuster LF; Duquia RP
    Int J Antimicrob Agents; 2016 Nov; 48(5):579-580. PubMed ID: 27720305
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study.
    Mattos KP; Lloret GR; Cintra ML; Gouvêa IR; Betoni TR; Mazzola PG; Moriel P
    Pigment Cell Melanoma Res; 2016 May; 29(3):388-90. PubMed ID: 26909746
    [No Abstract]   [Full Text] [Related]  

  • 5. Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy.
    Zavascki AP; Manfro RC; Maciel RA; Falci DR
    Ann Pharmacother; 2015 Oct; 49(10):1171-2. PubMed ID: 26187742
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.
    Zheng G; Cao L; Che Z; Mao E; Chen E; He J
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):41. PubMed ID: 29973293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperpigmentation on head and neck caused by polymyxin B: A rare case.
    Kaya F; Tuğcugil E
    Niger J Clin Pract; 2023 Sep; 26(9):1393-1395. PubMed ID: 37794556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility of intravenous pentoxifylline with other medications infused concurrently in preterm infants with late-onset sepsis.
    Lauterbach R; Strunk T; Patole S; Hurkała J; Pawlik D
    Acta Paediatr; 2018 Jul; 107(7):1288-1289. PubMed ID: 29524245
    [No Abstract]   [Full Text] [Related]  

  • 10. Antimicrobial dosing in neonates.
    Kontou A; Sarafidis K; Roilides E
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):239-242. PubMed ID: 28067058
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic.
    Elias LS; Konzen D; Krebs JM; Zavascki AP
    J Antimicrob Chemother; 2010 Oct; 65(10):2231-7. PubMed ID: 20685752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymyxin B-induced skin hyperpigmentation.
    Li YM; Milikowski C; Selvaggi G; Abbo LM; Skiada D; Galimberti F
    Transpl Infect Dis; 2020 Oct; 22(5):e13312. PubMed ID: 32386075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia.
    Kvitko CH; Rigatto MH; Moro AL; Zavascki AP
    J Antimicrob Chemother; 2011 Jan; 66(1):175-9. PubMed ID: 20961911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.
    Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT
    J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B.
    Zhou Y; Li Y; Xie X; Song L; Lan G; Sun B; Tang T; Yan H; Zhang B; Xu P
    Br J Clin Pharmacol; 2022 Nov; 88(11):4742-4750. PubMed ID: 35508710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-associated canine pemphigus vulgaris? Who knows!
    Olivry T
    Vet Dermatol; 2007 Oct; 18(5):378-9; author reply 379. PubMed ID: 17845628
    [No Abstract]   [Full Text] [Related]  

  • 17. Suspected polymyxin B-induced pemphigus vulgaris in a dog.
    Rybnícek J; Hill PB
    Vet Dermatol; 2007 Jun; 18(3):165-70. PubMed ID: 17470231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa.
    Schwartz RH
    Curr Med Res Opin; 2006 Sep; 22(9):1725-36. PubMed ID: 16968576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin testing after anaphylaxis to a topical Neosporin preparation.
    Schroer BC; Fox CC; Hauswirth DW
    Ann Allergy Asthma Immunol; 2008 Oct; 101(4):444. PubMed ID: 18939736
    [No Abstract]   [Full Text] [Related]  

  • 20. Patterns of polymyxin B use in eight major cities of China in its first year of use.
    Yu Z; Yu L; Zhu J
    J Glob Antimicrob Resist; 2020 Mar; 20():342-343. PubMed ID: 32084604
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.